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PScreening of Athletes
Pre-Participation Screening of Young Competitive
Athletes for Prevention of Sudden Cardiac Death
Domenico Corrado, MD, PHD,* Cristina Basso, MD, PHD,† Maurizio Schiavon, MD,‡
Antonio Pelliccia, MD,§ Gaetano Thiene, MD†
Padua and Rome, Italy
In 1982 a nationwide program of pre-participation screening including 12-lead electrocardiography (ECG) was
launched in Italy. The aim of this article is to examine whether this 25-year screening program should be consid-
ered a valid and advisable public health strategy. The analysis of data coming from the long-running Italian ex-
perience indicates that ECG screening has provided adequate sensitivity and specificity for detection of poten-
tially lethal cardiomyopathy or arrhythmias and has led to substantial reduction of mortality of young
competitive athletes by approximately 90%. Screening was feasible thanks to the Italian Health System, which
is developed in terms of health care and prevention services, and because of the limited costs of cardiovascular
evaluation in the setting of a mass program. On the basis of current scientific evidence the implementation of a
mass-screening program aimed to prevent athletic-field sudden cardiac death should be at least carefully consid-
ered by public health administrators worldwide. (J Am Coll Cardiol 2008;52:1981–9) © 2008 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.06.053c
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C“He who saves a single life saves the whole world.”
—Talmud Sanhedrin 4:5 (1)
udden death during sports is often the first and definitive
anifestation of an underlying cardiovascular disease, which
sually has a silent clinical course (2–6). Medical evaluation
efore competition offers the potential to detect still asymp-
omatic athletes with life-threatening heart diseases and to
rotect them from sudden cardiac death (SCD). A nation-
ide program of pre-participation screening of young com-
etitive athletes (YCAs), essentially based on 12-lead elec-
rocardiography (ECG), was launched in Italy in 1982 (7)
Fig. 1). The aim of this viewpoint article is to examine the
easons why this 25-year screening program should be
onsidered a valid and advisable public health strategy.
s SCD in the athlete a serious health problem? Cardio-
ascular fatalities during sports are rare; however, the public
ealth relevance of a disease/event is not necessarily linked
o its high occurrence (8). The sudden and unexpected
eath of a YCA is always a powerful and tragic event that
evastates families, other competitors, institutions (high
chool, college, or professional organization), sports medi-
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ccepted June 6, 2008.ine team, and the community. The sudden demise of a
CA has a tremendous impact on the media, because it
ffects young and apparently healthy individuals who are
egarded as the healthiest group in society and often as
eroes. Instinctively, everyone wonders what intervention
ight have prevented the death.
ncidence rates. The risk of SCD in athletes increases with
ge and is greater in male subjects. The incidence of SCD
mong U.S. high-school and college athletes (age range 12
o 24 years) has been estimated to be 1 in 100,000
articipants/year (4,5), whereas a prospective study in Italy
eported a yearly incidence of approximately 3 of 100,000
thletes (age range 12 to 35 years) (6). This discrepancy is
xplained by differences in age and gender of the 2 athletic
opulations, with the U.S. athletes carrying a substantially
ower risk because of younger age and inclusion of more
emale subjects.
elative risk. Athletic participation carries an inherent risk
f SCD (6,9). Adolescent and young adults involved in a
ports activity have an estimated risk of SCD 2.8 times
reater than that of their nonathletic counterparts (6). It is
he combination of physical exercise and underlying cardiovas-
ular disorders rather than exercise alone that triggers athletic-
eld arrhythmic cardiac arrest. This finding reinforces the
oncept that physicians and athletic trainers should ensure that
thletes are systematically screened to identify those with
otentially lethal heart diseases and to protect them against the
ncreased risk of SCD.
auses of sudden death. The primary purpose of pre-
articipation screening is to identify the cohort of ath-
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Pre-Participation Athletic Screening December 9, 2008:1981–9letes affected by cardiovascular
diseases at risk of SCD during
sports. A broad range of condi-
tions, including congenital and
inherited heart disorders, have
been reported to provoke SCD
in young athletes (2– 6,9 –13).
Cardiomyopathies have been
consistently implicated as the
primary cause of sports-related
cardiac arrest in YCAs, with
hypertrophic cardiomyopathy
HCM) accounting for one-third of fatal cases in the
.S. (4,5,11) and arrhythmogenic right ventricular car-
iomyopathy/dysplasia (ARVC/D) accounting for ap-
roximately one-fourth in Italy (2,3,6,13).
Systematic monitoring of fatalities among the young
opulation (age35 years) of the Veneto region of Italy has
hown that HCM rarely underlies SCD in YCAs, whereas
t is one of the leading causes of death among the nonath-
etic population of the same age range (2,6). This selective
eduction of SCD from HCM in Italian athletes cannot
e ascribed to ethnic and geographic differences in the
isease prevalence. Comparison between Italian findings
nd those reported by Burke et al. (11) in the U.S. shows
Abbreviations
and Acronyms
ARVC/D  arrhythmogenic
right ventricular
cardiomyopathy/dysplasia
HCM  hypertrophic
cardiomyopathy
SCD  sudden cardiac
death
YCA  young competitive
athlete
Figure 1 Flow Chart of the Italian Protocol of Cardiovascular P
Young competitive athletes are defined as individuals 12 to 35 years of age who a
athletic competitions. First-line examination includes family history, physical exami
subjects who have positive findings at the initial evaluation. Angio/EMB  contras
grammed ventricular stimulation; MRI  magnetic resonance imaging. Reprinted, wsimilar prevalence of HCM as a cause of nonsports-
elated SCD. Rather, the discrepancy might be reason-
bly explained by the unique exposure of the Italian athletic
opulation to systematic cardiovascular screening leading to
dentification and reduction of the SCD risk of athletes with
CM (2,3,14). As a consequence, other cardiovascular
onditions such as ARVC/D, premature coronary artery
isease, and congenital coronary anomalies have thereby
ome to account for a greater proportion of all SCD in
talian athletes. Arrhythmogenic right ventricular cardio-
yopathy/dysplasia is a worldwide increasingly recognized
ause of morbidity and mortality, mostly in young individ-
als and athletes (15–17). In the past, the misconception
hat ARVC/D was a Venetian disease relied on the un-
wareness of its clinical and pathologic features in other
ountries, where it remained largely underdiagnosed by
linicians and pathologists for a long time (18).
s an ECG an Accurate Test for Early Detection
f Athletes With At-Risk Cardiovascular Diseases?
deally, an efficient pre-participation screening test should
iss very few individuals with at-risk cardiovascular dis-
ases, although a proportion of false positive results can be
ccepted (8).
rticipation Screening
aged in a regular fashion in exercise training as well as participating in official
, and 12-lead electrocardiography (ECG); additional tests are requested only for
graphy/endomyocardial biopsy; EPS  electrophysiologic study with pro-
rmission, from Corrado et al. (3).re-Pa
re eng
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ith pe
S
s
t
s
t
e
l
h
e
f
h
g
p
c
t
f
a
n
m
p
(
n
d
p
I
p
a
c
W
c
B
(
f
t
c
Y
m
t
c
s
c
Y
S
b
p
P
q
d
n
a
f
c
i
s
l
t
d
s
h
f
s
e
E
s
a
c
l
p
(
s
d
m
c
u
u
t
h
C
s
n
t
g
r
a
e
c
f
l
e
e
I
D
T
a
t
m
a
r
c
t
s
I
d
(
1983JACC Vol. 52, No. 24, 2008 Corrado et al.
December 9, 2008:1981–9 Pre-Participation Athletic Screeningcreening sensitivity. Most cardiovascular conditions re-
ponsible for SCD in YCAs are clinically silent and unlikely
o be suspected or diagnosed on the basis of spontaneous
ymptoms (2–6,9–13). This explains why a screening pro-
ocol based solely on the athlete’s history and physical
xamination is of marginal value for identification of ath-
etes at risk for SCD (19). The Italian screening program
as shown that ECG, in addition to history and physical
xamination, has a substantial incremental value for identi-
ying asymptomatic athletes who have potentially lethal
eart disorders and might be as sensitive as echocardio-
raphic examination. Among 33,735 athletes undergoing
re-participation screening at the Center for Sport Medi-
ine in Padua, 3,016 (8.9%) were referred for additional
esting, mainly echocardiography, and 621 were disqualified
or cardiovascular reasons (1.8%) (2). Of 22 athletes (all
symptomatic) with a clinical and echocardiographic diag-
osis of HCM, 18 (82%) showed 1 or more ECG abnor-
alities at pre-participation evaluation and 5 (23%) had
remature ventricular beats. Conversely, only 5 athletes
23%) had a family history or a cardiac murmur or both.
An absolute value of screening sensitivity for HCM could
ot be derived from these data, because systematic echocar-
iographic findings were not available. However, the 0.07%
revalence of HCM found in YCAs of the Veneto region of
taly, evaluated by ECG screening, was similar to the 0.10%
revalence reported for young white individuals in the U.S.,
ssessed by echocardiography (20).
Other ECG-detectable diseases responsible for SCD in-
lude ARVC/D, dilated cardiomyopathy, Wolff-Parkinson-
hite syndrome, and ion channel diseases such as Lènegre
onduction disease, long and short-QT syndromes, and
rugada syndrome (Table 1). Overall, these conditions
including HCM) account for approximately two-thirds of
atal events in YCAs, on the basis of published series from
he U.S. and Italy (3).
In contrast, the possibility of detecting either premature
oronary atherosclerosis or anomalous coronary artery in
CAs is limited by the scarcity of baseline ECG signs of
yocardial ischemia (2,3). Although additional exercise
esting might enhance the potential to discover ischemic
onditions, its systematic use is limited by the low test
ensitivity/specificity for coronary artery diseases (including
ongenital coronary arteries) in the general population of
CAs.
creening specificity. A screening test is not intended to
e diagnostic; it separates apparently well persons who
robably have a disease from those who probably do not.
ersons with positive or suspicious findings will be subse-
uently referred for further clinical evaluation to achieve a
efinitive diagnosis.
An ECG has been traditionally considered to be a
onspecific and noncost-effective screening tool in the
thletic population, because of its presumed high level of
alse positive results (19). This has been the result of the
oncept that physiologic ECG changes, which usually occur en trained athletes as an expression of heart adaptation to
ustained physical exercise, overlap significantly with patho-
ogic ECG abnormalities seen in the cardiovascular diseases
hat cause SCD (19,21,22). The Italian experience has
isproved this general idea that ECG is a nonspecific
creening test. Among 42,386 athletes initially screened by
istory, physical examination, and ECG, the percentage of
alse positives (i.e., athletes with a normal heart but positive
creening findings) requiring additional testing, mainly
chocardiography, did not exceed 9% (23).
CG interpretation. Italian sports physicians who have a
pecific training, scientific background, and medical skill for
ppropriate interpretation of an athlete’s ECG played a
rucial role for achieving such an adequate accuracy of first
ine cardiovascular screening (3,22). Such physicians attend
ostgraduate residency training programs in sports medicine
and sports cardiology) full-time for 4 years and work in
ports medical centers, either public or private, specifically
evoted to periodical screening of athletes.
Misinterpretation of ECG by inexperienced physicians
ight lead to serious medical consequences and reduce
ost-utility of the screening process (22). Athletes might
ndergo an expensive diagnostic work-up or might be
nnecessarily disqualified from competition for abnormali-
ies, such as isolated voltage criteria for left ventricular
ypertrophy, that fall within the normal range for athletes.
onversely, signs of potentially lethal organic heart disease,
uch as T-wave inversion, might be misinterpreted as
ormal variants of an athlete’s ECG. Appropriate interpre-
ation of an athlete’s ECG requires the distinction of 2 main
roups of abnormalities on the basis of their prevalence,
elation to exercise training, inherent cardiovascular risk,
nd need for further clinical investigation to confirm (or
xclude) an underlying cardiovascular disease (Fig. 2). Ac-
ording to the long-term Italian experience, limitation of
urther expensive diagnostic work-up to the fewer ath-
etes showing Group 2 ECG changes results in a consid-
rable cost-saving and improvement of screening cost-
ffectiveness (22).
s There an Effective Treatment for Athletes
iagnosed With Heart Diseases at an Early Stage?
he importance of identification by ECG screening of
symptomatic athletes with cardiovascular diseases relies on
he concrete possibility of SCD prevention by lifestyle
odification, including restriction of competitive sports
ctivity and concomitant prophylactic treatment by antiar-
hythmic drugs, beta-blocker drugs, and implantable
ardioverter-defibrillator therapy. Athletes who did not ob-
ain eligibility for competition because of cardiovascular rea-
ons were found to have a good long-term clinical course (2).
n particular, none of the 22 asymptomatic athletes who were
isqualified for HCM died during a 7.8-year follow-up period
2). Of note, 3 of these former athletes with HCM afterwards
xperienced serious arrhythmic complications that were suc-
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Pre-Participation Athletic Screening December 9, 2008:1981–9essfully treated by beta-blocker drugs and/or amiodarone.
herefore, the favorable long-term outcome was the result of
oth disqualification from competitive sports and the subse-
uent close follow-up and clinical management.
oes Pre-Symptomatic Identification of Athletes
ith Cardiovascular Diseases Reduce Mortality?
he final objective of screening athletes for cardiovascular
iseases is to prevent SCD during sports. A time-trend
nalysis of the incidence of SCD in YCAs in the Veneto
egion of Italy over 26 years (1979 to 2004) demonstrated a
harp decline of mortality rates after the introduction of the
ationwide screening program (23). The annual incidence
f SCD in athletes decreased by 89%, from 3.6/100,000
CG Features of Cardiac Diseases Detectable at Pre-Participation
Table 1 ECG Features of Cardiac Diseases Detectable at Pre-P
Disease QTc Interval P-Wave PR Interval QR
Hypertrophic
cardiomyopathy
Normal (Left atrial
enlargement)
Normal Increas
mid-
lead
“q” w
infer
later
LBBB
Arrhythmogenic right
ventricular
cardiomyopathy/
dysplasia
Normal Normal Normal Prolong
in rig
lead
in rig
lead
volta
in fro
(RBB
Dilated
cardiomyopathy
Normal (Left atrial
enlargement)
(Prolonged
0.21 s)
LBBB
Myocarditis (Prolonged) Normal Prolonged
0.21 s
(Abnorm
Long-QT syndrome Prolonged
440 ms
in male
subjects,
460 ms
in female
subjects
Normal Normal Normal
Brugada syndrome Normal Prolonged
0.21 s
S1S2S3
(RBB
Lenègre disease Normal Normal Prolonged
0.21 s
RBBB; R
LBBB
Short-QT syndrome Shortened
300 ms
Normal Normal Normal
Pre-excitation
syndrome (WPW)
Normal Normal Shortened
0.12 s
Delta w
Coronary artery
diseases†
(Prolonged) Normal Normal (Abnorm
ess common or uncommon electrocardiography (ECG) findings are reported in parentheses. *Abn
ore leads; †coronary artery diseases  either premature coronary atherosclerosis or congenital
AV  atrioventricular; LAD  left axis deviation of 30° or more; LBBB  left bundle branch
Tc  QT interval corrected for heart rate by Bazett’s formula; VT  either nonsustained or sustathlete/years in the pre-screening period (1979 to 1981) to p.4/100,000 athlete-years in the late-screening period (1993
o 2004) (Fig. 3). By comparison, the incidence of SCD in
he unscreened nonathletic population of the same age did
ot change significantly over that time. The decline in death
ate started after mandatory screening was launched and
ersisted to the late screening period. Most of the reduced
eath rate was due to fewer cases of SCD from cardiomy-
pathies. A parallel study of eligibility for competitive sports
howed that the proportion of athletes identified and
isqualified because of cardiomyopathies (mostly HCM and
RVC/D) doubled from the early to the late screening
eriod. This substantiates the concept that the decrease of
ortality from cardiomyopathy was the result of increasing
dentification over time of affected athletes at pre-
ning in Young Competitive Athletes
ipation Screening in Young Competitive Athletes
plex ST-Segment Interval T-Wave Arrhythmias
ages in
-cordial
rmal
in
/or
s; (LAD,
ta wave)
Down-sloping
(up-sloping)
Inverted in mid-left
pre-cordial leads;
(giant and
negative in the
“apical” variant)
(Atrial fibrillation);
(PVB); (VT)
10 ms
-cordial
lon wave
-cordial
ced
0.5 mV
ads;
(Up-sloping in right
pre-cordial leads)
Inverted in right
pre-cordial leads
PVB with an LBBB
pattern; (VT with
an LBBB pattern)
Down-sloping
(up-sloping)
Inverted in inferior
and/or lateral
leads
PVB; (VT)
waves)* Down- or up-sloping Inverted in 2 leads (Atrial arrhythmias);
(PVB); (2nd or
3rd degree AV
block); (VT)
Normal Bifid or biphasic in
all leads
(PVB); (torsades de
pointes)
rn;
)
Up-sloping “coved-
type” in right
pre-cordial leads
Inverted in right
pre-cordial leads
(Polymorphic VT);
(atrial fibrillation)
(sinus
bradycardia)
LAD; Normal Secondary changes (2nd or 3rd degree
AV block)
Normal Normal Atrial fibrillation
(polymorphic VT);
Secondary hanges Secondary changes Supraventricular
tachycardia;
(atrial fibrillation)
waves)* (Down- or up-sloping) Inverted in 2 leads PVB; (VT)
“q” waves 0.04 s in duration or 25% of the height of the ensuing R-wave or QS pattern in 2 or
ry anomalies. Modified from Corrado et al. (3).
BBB  right bundle branch block; PVB  either single or coupled premature ventricular beats;
ntricular tachycardia; WPW  Wolff-Parkinson-White.Scree
artic
S Com
ed volt
left pre
s; abno
aves*
ior and
al lead
); (del
ed 1
ht pre
s; epsi
ht pre
s; redu
ges 
ntal le
B)
al “q”
patte
B/LAD
BBB/
ave
al “q”
ormal
coronaarticipation screening.
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December 9, 2008:1981–9 Pre-Participation Athletic Screeningritical Appraisal
hese data showing the substantial reduction of mortality
mong Italian athletes after screening implementation have
aised a number of criticisms.
tudy design. Thompson and Levine (24) stressed that the
talian study was not a controlled comparison of screening
ersus nonscreening of YCAs but an observational
opulation-based investigation.
The study was not a randomized trial, and unequivocal
onclusions that the reduced mortality was solely the con-
equence of the screening process cannot be drawn. How-
ver, the strong cause-effect relationship between imple-
entation of the screening program and the substantial
eduction (by 89%) of SCD in Italian athletes should
emove all doubt of the efficacy of screening to identify
thletes with at-risk cardiovascular conditions and its ability
o save lives. The study (23) showed that: 1) there was a
oincident timing between decline of SCD in YCAs and
creening implementation in Italy; 2) most of the reduced
ncidence of SCD was due to fewer deaths from cardiomy-
pathies, and it was accompanied by the concomitant
ncrease of the proportion of YCAs with cardiomyopathies
Figure 2 Classification of ECG Abnormalities in the Athlete
Common electrocardiography (ECG) abnormalities: up to 80% of trained athletes e
early repolarization, incomplete right bundle branch block (RBBB) and pure increas
physiologic cardiovascular adaptation to sustained physical exertion and do not re
associated with an increase of cardiovascular risk and allow eligibility to competiti
includes uncommon ECG patterns (5%) such as ST-segment and T-wave repolari
ventricular arrhythmias (Group 2). These ECG abnormalities are unrelated to athlet
vascular disorders, notably cardiomyopathies and cardiac ion channel diseases, a
fied from Corrado et al. (22). LBBB  left bundle branch block.ho were identified and disqualified from competition at yhe Center for Sports Medicine in Padua during the same
ime interval; and 3) during the study period, the incidence
f SCD did not change among the unscreened nonathletic
opulation of the Veneto region of the same age range.
ortality rates. It has been argued that the annual death
ate of Italian competitive athletes before mandatory screen-
ng was higher and the late-screening annual death rate was
oughly similar to that reported by the National Center for
atastrophic Sport Injury Research (NCCSIR) in U.S.
igh-school and college athletes (5,24). It has been thus
uggested that no screening process or less formal screening
rocess practiced in the U.S. might have been as effective as
he Italian program. However, the 2 athletic populations
ere noncomparable with regard to gender and age, so that
he differences in mortality rates are explained by the
ecognized greater risk of SCD in male and older athletes
5,6). According to the NCCSIR estimates, the overall rate
f SCD among U.S. high-school and college participants
as 5-fold higher for male than for female athletes (0.75/
00,000 athletes/year vs. 0.13/100,000 athletes/year). Male
ollege athletes (age range 20 to 24 years) had twice the
stimated death rate of their high-school (age range 12 to 19
ECG changes such as sinus bradycardia, first degree atrioventricular (AV) block,
RS voltages (Group 1). Such common ECG changes are the consequence of the
e presence of an underlying cardiovascular disease. Therefore, they are not
rts without additional evaluation. Uncommon ECG abnormalities: this subset
abnormalities, pathological Q waves, intraventricular conduction defects, and
ditioning and should be regarded as an expression of possible underlying cardio-
s associated with an inherent increased risk of sudden arrhythmic death. Modi-xhibit
e of Q
flect th
ve spo
zation
ic con
nd thuears) counterparts (1.45/100,000 athletes/year vs. 0.66/
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Pre-Participation Athletic Screening December 9, 2008:1981–900,000 athletes/year) (5). The mortality rate of the Italian
thletic population was expectedly higher (approximately
.60/100,000 athletes during the pre-screening era), because
t included predominantly male (82%) and older (age range
2 to 35 years) athletes (6).
ata accuracy and denominators. Whereas the Italian
ata were systematically gathered from a well-defined geo-
raphic area (the Veneto region of Italy) according to a
rospective study design, the U.S. SCD rates were mostly
ased on retrospective analysis of data collected by the
CCSIR, new accounts, informal communications, and
eports (4,5). Although these sources of information were
he best available in the U.S., reasonable concerns exist
egarding their reliability for estimation of an athlete’s SCD
ate due to unavoidable limitations inherent in the data
ollection and the retrospective study design. As recognized
y Van Camp et al. (5), all SCDs in athletes occurring in the
.S. were unlikely to have been reported by the NCCSIR,
eading to an incorrectly low number of events and under-
stimation of mortality rates. The accuracy of the determi-
ation of incidence rates of SCD among U.S. athletes is
uestionable, because denominator data did not reflect the
eal number of active athletes in each year but rather the total
articipation figures divided by an estimate of the average
umber of sports in which each high-school and college
thlete participated.
ther factors. The alternative hypothesis—that Italian
eneral doctors not involved in the screening process might
ave detected more individuals with cardiomyopathy over
ime, thus removing potential victims from the athletic
ool—can not be completely excluded, although it is purely
peculative (24). What the Italian screening data undeniably
emonstrated, instead, is that reduction in athlete mortality
Figure 3 Annual Incidence Rates of Sudden Cardiac Death Amo
Athletes and Unscreened Nonathletes in the Veneto R
Modified from Corrado et al. (23).aralleled the increasing number of athletes with cardiomy- ppathies (both HCM and ARVC/D) who were identified
nd disqualified at pre-participation screening over the
tudy period (23).
lternative Preventive Strategies
here are not competing public health strategies either
ore efficient or cost-effective than ECG screening for
revention of SCD in the athlete.
Pre-participation cardiovascular screening has tradition-
lly been performed in the U.S. by means of history
personal and family) and physical examination, without
2-lead ECG or other testing. This screening method is
urrently recommended by the American Heart Associa-
ion, although it has a recognized limited power to detect
otentially lethal cardiovascular abnormalities in young
thletes (19). Glover and Maron (25) found that, of 134
igh-school and collegiate athletes experiencing SCD who
ad undergone a pre-participation medical evaluation by
istory and physical examination, only 3% were suspected of
aving cardiac disease and eventually 1% received an
ccurate diagnosis. The Italian screening program has
hown that ECG makes the difference. Among 22 athletes
ith HCM who were detected by ECG screening at the
enter for Sport Medicine in Padua and disqualified from
ompetition, only 5 (23%) would had been identified on the
asis of a positive family history, symptoms, or abnormal
hysical findings, in the absence of an ECG (2).
The presence of a free-standing, automated external
efibrillator at sporting events might be a valuable back-up
or conditions unrecognized by ECG screening such as
oronary artery diseases, either atherosclerotic or congenital,
ut should be considered neither a substitute for pre-
creened Competitive
n of Italy From 1979 to 2004ng S
egioarticipation evaluation nor a justification for participation
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December 9, 2008:1981–9 Pre-Participation Athletic Screeningn competitive sports of athletes with at-risk heart diseases.
hances for on-field successful resuscitation are remote,
ven if cardiopulmonary resuscitation is started immediately
nd defibrillation equipment is readily available. Drezner
nd Rogers (26) reported that only 11% of athletes with
nderlying cardiomyopathy survived from athletic-field car-
iac arrest, despite a witnessed collapse, timely cardiopul-
onary resuscitation, and prompt defibrillation.
ost-Benefit Considerations
creening of large athletic populations has a significant
ocioeconomic impact. How pre-participation screening
ight be generalizable to other countries is a complex issue
hat goes beyond the scope of the present review article.
trategies for implementing the screening program depend
n the particular socioeconomic and cultural background as
ell as on the specific medical systems in place in different
ountries. In Italy screening is made feasible thanks to the
ational Health System, which is developed in terms of
ealth care and prevention services, and to the limited costs
f cardiovascular evaluation in the setting of a mass program
3). The cost of performing a pre-participation cardiac
istory, physical examination, and ECG by qualified phy-
icians has been estimated to be €30/athlete ($45 U.S.).
he screening cost is covered by the athlete or by the
thletic team, except for athletes younger than age 18 years,
or whom the expense is supported by the National Health
ystem. Moreover, the cost of further evaluation of athletes
ith positive findings at first-line examination is smaller
re-Participation Athletic Screening in Other European Countries
Table 2 Pre-Participation Athletic Screening in Other European
Country Medical/Sports Associations
Luxembourg National Sports Ministry, Olympic Medical Committee,
National Association of Sports Physicians
Sweden National Board of Health and Welfare, National Federations
of Sports
Norway Norwegian Football Association Medical Committee
Germany German Association of Sports Medicine, National Sports
Federations
Poland Ministry of Sports and Tourism, Ministry of Health,
Polish Cardiac Society, Sports Federations
France National Sports Ministry
French Society of Cardiology
Scotland Government Department of Health
England British Lawn Tennis and Football Associations
Greece Hellenic College of Sports Medicine, National Sports Federations
Belgium National Sports Federations
Spain High Sports Government Council
The
Netherlands
Working group of Cardiovascular Prevention and Rehabilitation,
National Olympic Committee, National Sports Federations,
Netherlands Society of Cardiology
CG electrocardiography; competitive athletes athletes engaged in a regular fashion in exercis
lite athletes  athletes of I and II leagues; professional athletes  elite athletes engaged in athletic achan expected on the basis of the presumed low specificity of
he athlete’s ECG. The percentage of athletes requiring
dditional testing, mainly echocardiography, has been found
o be 9%, with a modest proportional impact on cost
2,23).
Costs of infrastructure and training courses for pre-
articipation screening must also be taken into account in
he calculation of the overall screening cost (3). Strategies
or screening implementation should be in the hands of
ealth care policymakers and service providers, with their
rogram development based on the specific national health
nd socioeconomic systems (27).
The young age of the screened athletic population and
he genetic nature of the causes of SCD in this age group
rofoundly impacts cost-benefit considerations. Unlike
lder patients with coronary artery disease or heart failure,
dolescents and young adults diagnosed with a genetic
isease at risk of arrhythmic SCD will survive for many
ecades with normal or nearly normal life expectancy,
hanks to restriction from competition and prophylactic
herapy against life-threatening arrhythmias. This large
umber of life-years saved influences cost-effectiveness anal-
sis and explains why all reports on ECG screening of
oung individuals have provided cost estimates/year of life
aved well below $50,000, which is the traditional threshold
o consider a health intervention cost-effective (27–30). The
enefit of pre-participation evaluation goes beyond the
etection of index athletes with an inherited heart disease,
ecause it enables cascade screening of relatives and results
tries
arget Athletic Population Screening Protocol
petitive athletes of all sports History, physical examination, ECG (required)
athletes of all sports History, physical examination, ECG (recommended)
ssional football athletes History, physical examination, ECG,
echocardiography (required)
ssional athletes of all sports History, physical examination, ECG,
echocardiography, exercise testing (required)
petitive athletes (age 23
s) of all sports and national
am members
History, physical examination, ECG (required)
ssional athletes of all sports History, physical examination, ECG,
echocardiography, exercise testing (required)
petitive athletes of all sports History, physical examination, ECG (recommended)
petitive football athletes
16 yrs)
History, physical examination, ECG (required)
petitive athletes History, physical examination, ECG (required)
petitive athletes of all sports History, physical examination, ECG (recommended)
tes of cycling and
otocross sports
History, physical examination, ECG (required)
petitive athletes of all sports History, physical examination, ECG (recommended)
petitive athletes of all sports
athletes of cycling, motor
d flying sports, and diving
History, physical examination, ECG (recommended)
History, physical examination, ECG (required)
g and participating in official athletic competitions as an organized team or individual sport event;Coun
T
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Elite
Profe
Profe
Com
yr
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Profe
Com
Com
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Com
Athle
m
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antivities with a labor contract.
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embers and saving additional lives.
isqualification From Competitive Sports
thlete disqualification might be associated with an impor-
ant individual cost in terms of health, contentment, and
ven future opportunity for professional sports. However,
he risk of SCD associated with competitive sports in the
etting of life-threatening cardiovascular disease is a con-
rollable risk factor, and the devastating impact of even
nfrequent fatal events in the young athletic population
ustifies appropriate restriction from competition (31).
hanks to the long-running Italian experience, we have
earned the lesson that screening athletes for cardiomyopa-
hies and arrhythmias is most productive in preventing
thletic-field SCD, whereas the exclusion from competition
f many other young athletes with nonlethal diseases is
ore arbitrary and not as productive. The prevalence of
talian athletes who were diagnosed and disqualified because
f cardiovascular diseases was approximately 2%; however,
rue potentially lethal conditions such as cardiomyopathies,
hythm and conduction disturbances, long-QT syndrome,
alvular heart disease (predominantly aortic valve stenosis),
remature coronary artery disease, and Marfan syndrome
ere identified in a smaller subgroup not exceeding 0.2%
23). This has significant implications for optimizing sports
ligibility guidelines and management of YCAs with car-
iovascular diseases in the future. The main objective should
e to reduce the number of unnecessary disqualifications
nd to adapt (rather than restrict) sports activity in relation
o the specific cardiovascular risk.
onclusions
re-participation cardiovascular evaluation of competitive
thletes essentially based on ECG seems, according to the
ong-term Italian experience, to be a lifesaving strategy that
dequately meets the criteria for a good screening program
8): 1) the risk of SCD during sports represent a serious
ealth problem; 2) ECG screening allows identification of
till-asymptomatic athletes with at-risk cardiovascular diseases;
) an effective management strategy exists on the basis of
estriction of life-threatening training/competition and subse-
uent clinical treatment; and most importantly, 4) early detec-
ion and management of athletes favorably modifies the out-
ome of the underlying disease and leads to reduction of SCD.
It is noteworthy that a 25-year interval was required to
enerate these Italian results. Until other studies, either
bservational or randomized, on athletic populations of
omparable size and follow-up are conducted, the existing
ata provide good evidence that ECG screening decreases
he risk of SCD in athletes. Accordingly, pre-participation
CG screening is currently recommended by the Interna-
ional Olympic Committee (“Lausanne Recommenda-
ions”) (32) as well as by most European Cardiologic
ocieties and Sports Medical Federations (Table 2). How-ver, major obstacles for a definitive screening launch still
xist and rely on the lack of national legislation. Thanks to
he continuous and cooperative efforts of Medical Societies
nd Sports Organizations, the hope is that in the near future
ublic health care policymakers will actually consider im-
lementation of such a screening program aimed to reduce
he number of preventable athletic-field SCDs.
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